Copyright
©The Author(s) 2021.
World J Hepatol. Nov 27, 2021; 13(11): 1743-1752
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1743
Published online Nov 27, 2021. doi: 10.4254/wjh.v13.i11.1743
Group I | Group II | P value | |
HCC with previous DAAs (n = 151) | HCC without previous DAAS (n = 346) | ||
Hypertension | 56 (37.1) | 135 (39.0) | 0.68 |
DM | 56 (37.1) | 113 (32.7) | 0.33 |
Smoking | 73 (48.3) | 121 (35.0) | 0.005a |
Surgical operations | 32 (21.2) | 101 (29.2) | 0.06 |
Blood transfusion | 23 (15.2) | 87 (25.1) | 0.01a |
Jaundice | 60 (39.7) | 154 (44.5) | 0.32 |
Ascites | 90 (59.6) | 197 (56.9) | 0.58 |
LL edema | 48 (31.8) | 143 (41.3) | 0.07 |
Hepatic encephalopathy | 14 (9.3) | 61 (17.6) | 0.01a |
- Citation: Fouad M, El Kassas M, Ahmed E, El Sheemy R. Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients. World J Hepatol 2021; 13(11): 1743-1752
- URL: https://www.wjgnet.com/1948-5182/full/v13/i11/1743.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i11.1743